沙库巴曲缬沙坦治疗高血压合并慢性心力衰竭患者的临床疗效

doi:10.3969/j.issn.1671-7171.2025.06.027

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1254 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the clinical efficacy of sacubitril valsartan in the treatment of hypertension with chronic heart failure. 【Methods】A total of 98 patients with hypertension and chronic heart failure admitted to the two hospitals from February 2019 to March 2023 were selected. The patients were randomly divided into the observation group and the control group using a random number table, with 49 patients in each group. Blood pressure, serum N-terminal pro brain natriuretic peptide (NT-proBNP), angiotensin Ⅱ (Ang Ⅱ) levels, cardiac function indicators [left ventricular end systolic diameter (LVESD), left ventricular end diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF)], and medication safety were compared between two groups before and after treatment. 【Results】The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, the systolic and diastolic blood pressure in both groups were lower than those before treatment, and the value of the observation group was lower than that of the control group, with a statistically significant difference (P<0.05). The serum levels of NT-proBNP and AngⅡ in both groups were lower than those before treatment, and those in the observation group were lower than those in the control group with statistically significant difference (P<0.05). LVESD and LVEDD after treatment in both groups were lower than those before treatment, while LVEF was higher than that before treatment (P<0.05). After treatment, both LVESD and LVEDD of the observation group were lower than those of the control group, while LVEF was higher than that of the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】Sacubitril valsartan can reduce the levels of serum AngⅡ and NT-proBNP in patients with hypertension and chronic heart failure, lower blood pressure, improve cardiac function. And it is safe and reliable.

Key words： Hypertension Heart Failure Chronic Disease Valsartan Treatment Outcome

Received: 10 December 2024

PACS:

R542.22

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WAN Jun
	WANG Wenyuan

Cite this article:

WAN Jun,WANG Wenyuan. Clinical Effect of Shakubactri Valsartan in the Treatment of Chronic Heart Failure with Hypertension[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(6): 1007-1010.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.06.027 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I6/1007

[1] SLIVNICK J, LAMPERT B C.Hypertension and heart failure[J].Heart Fail Clin,2019,15(4):531-541.
[2] 唐彪,傅慎文. 贝那普利与美托洛尔联合治疗对老年原发性高血压合并慢性心力衰竭患者心功能指标、昼夜节律变化及心率变异性的影响[J].中国医师杂志,2020,22(9):1413-1416.
[3] DOCHERTY K F, VADUGANATHAN M, SOLOMON S D, et al.Sacubitril/valsartan: neprilysin inhibition 5 years after PARADIGM-HF[J].JACC Heart Fail,2020,8(10):800-810.
[4] HEYSE A, MANHAEGHE L, MAHIEU E, et al.Sacubitril/valsartan in heart failure and end-stage renal insufficiency[J].ESC Heart Fail,2019,6(6):1331-1333.
[5] 中国高血压防治指南修订委员会,高血压联盟(中国),中华医学会心血管病学分会,等. 中国高血压防治指南( 2018年修订版)[J].中国心血管杂志,2019,24(1):24-56.
[6] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122.
[7] BREDY C, MINISTERI M, KEMPNY A, et al. New York Heart Association (NYHA) classification in adults with congenital heart disease: relation to objective measures of exercise and outcome[J].Eur Heart J Qual Care Clin Outcomes,2018,4(1):51-58.
[8] 王清传,张志敏,李喆,等. 血浆可溶性生长刺激表达基因2蛋白水平对门诊心力衰竭患者预后的影响[J].海军医学杂志,2020,41(5):561-563.
[9] SORRENTINO M J.The Evolution from hypertension to heart failure[J].Heart Fail Clin,2019 ,15(4):447-453.
[10] BORLAUG B A.Evaluation and management of heart failure with preserved ejection fraction[J].Nat Rev Cardiol,2020,17(9):559-573.
[11] 赵金艳,崔少楠,曹月娟. 沙库巴曲缬沙坦钠治疗老年高血压慢性心力衰竭的疗效观察[J].中华老年心脑血管病杂志,2021,23(12):1268-1271.
[12] SCHMITT W, RÜHS, BURGHAUS R, et al.NT-proBNP qualifies as a surrogate for clinical end points in heart failure[J].Clin Pharmacol Ther,2021,110(2):498-507.
[13] SON Y J, CHOI J, LEE H J.Effectiveness of nurse-led heart failure self-care education on health outcomes of heart failure patients: a systematic review and meta-analysis[J].Int J Environ Res Public Health,2020,17(18):6559.
[14] 黄婕,韦方练,李丹,等. 高血压合并慢性心力衰竭患者血清AngⅡ、ALD、NT-pro-BNP水平及与预后的相关性研究[J].国际检验医学杂志,2021,42(15):1797-1801.
[15] 贾红丹,丛洪良,赵云凤,等. 沙库巴曲缬沙坦治疗慢性心力衰竭患者的疗效观察[J].天津医药,2019,47(10):1076-1080.
[16] 张小红,李俭强,李天开,等. 沙库巴曲缬沙坦对急性失代偿性心力衰竭患者短期预后的改善作用[J].临床内科杂志,2022,39(10):671-674.
[17] 何云,李小红,张燕,等. 沙库巴曲缬沙坦治疗急性失代偿射血分数降低心力衰竭患者的有效性和安全性[J].西部医学,2022,34(11):1673-1678.